US Stock MarketDetailed Quotes

ONCT Oncternal Therapeutics

Watchlist

7.0500
+0.0350+0.50%

Close Jul 2 16:00 ET

20.87MMarket Cap-571P/E (TTM)

Oncternal Therapeutics Stock Forum

Jaguar8

May 30 15:12

NEWS

$Oncternal Therapeutics(ONCT.US)$
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Trytosaveabit

Apr 18 08:01

Update

$Oncternal Therapeutics(ONCT.US)$ Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Trytosaveabit

Jan 8 08:16

Update

$Oncternal Therapeutics(ONCT.US)$ Oncternal Therapeutics Enrolls Patients In Third Dosing Cohort Of Phase 1/2 Study Of ONCT-534

Trytosaveabit

Oct 26, 2023 08:05

News

$Oncternal Therapeutics(ONCT.US)$ Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
5 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE

Moomoo AI

Oct 25, 2023 08:06

Dr. Smith's advisory role will help shape the clinical strategy for ONCT-534. Her expectation is that the drug could deal with escape mechanisms of a specific prostate cancer, boosting its prospective efficiency and market validity.